Used in the treatment of chronic inflammatory diseases, particularly cardiovascular conditions linked to inflammation. Targets interleukin-6 (IL-6) pathway to reduce systemic inflammation, showing promise in patients with atherosclerosis and high levels of C-reactive protein. Investigated for reducing the risk of major adverse cardiovascular events in high-risk individuals, especially those with underlying inflammatory conditions such as rheumatoid arthritis or chronic kidney disease. Its mechanism helps block IL-6 trans-signaling, which plays a key role in vascular inflammation without broadly suppressing the immune system. Currently in clinical development for cardiovascular indications, offering a targeted anti-inflammatory approach distinct from lipid-lowering therapies.